{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:56:06Z","timestamp":1792616166136,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["bprch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.beha.2013.09.003","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T20:06:42Z","timestamp":1380658002000},"page":"327-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): Cause or consequence?"],"prefix":"10.1016","volume":"26","author":[{"given":"Thorsten","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2013.09.003_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0248-8663(01)00367-8","article-title":"Myelodysplasies et maladies syst\u00e9miques: une association non fortuite","volume":"22","author":"Berthier","year":"2001","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.beha.2013.09.003_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2141.1995.tb05310.x","article-title":"Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy","volume":"91","author":"Enright","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2013.09.003_bib3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/acr.20504","article-title":"Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study","volume":"63","author":"de Hollanda","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.beha.2013.09.003_bib4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","article-title":"An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long term outcome in 155 patients","volume":"43","author":"Reinhold Keller","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beha.2013.09.003_bib5","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/1529-0131(199808)41:8<1493::AID-ART21>3.0.CO;2-5","article-title":"Cytogenetic abnormalities and therapy related myelodysplastic syndromes in rheumatic disease","volume":"41","author":"McCarthy","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beha.2013.09.003_bib6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood-2004-05-2017","article-title":"Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome","volume":"106","author":"Sloand","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib7","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2007.11.9214","article-title":"Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy","volume":"26","author":"Sloand","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.09.003_bib8","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2010-04-277921","article-title":"T\u00a0cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy","volume":"117","author":"Sloand","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib9","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1200\/JCO.2010.29.7010","article-title":"Alemtuzumab treatment of intermediate 1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions","volume":"28","author":"Sloand","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.09.003_bib10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.leu.2404747","article-title":"Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin","volume":"21","author":"Lim","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2013.09.003_bib11","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.beha.2013.09.003_bib12","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.4049\/jimmunol.1200602","article-title":"Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome","volume":"189","author":"Mailloux","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beha.2013.09.003_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/39.4.417","article-title":"Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study","volume":"39","author":"Hamidou","year":"2000","journal-title":"Rheumatology"},{"key":"10.1016\/j.beha.2013.09.003_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/10428190109097683","article-title":"Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis Behcet's syndrome","volume":"42","author":"Kimura","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2013.09.003_bib15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/ajmg.a.32756","article-title":"Constitutional trisomy 8 and Beh\u00e7et syndrome","volume":"149A","author":"Becker","year":"2009","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.beha.2013.09.003_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/ard.2003.012948","article-title":"Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor 1 (IRF 1) expression","volume":"63","author":"Giannouli","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.beha.2013.09.003_bib17","first-page":"S436","article-title":"Vasculitides and cancers: 60 cases","volume":"50","author":"Fain","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beha.2013.09.003_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/sarh.2001.27717","article-title":"Systemic medium size vessel vasculitis associated with chronic myelomonocytic leukaemia","volume":"31","author":"Hamidou","year":"2001","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.beha.2013.09.003_bib19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/RHU.0b013e3181776bde","article-title":"Beh\u00e7et disease associated with myelodysplastic syndrome","volume":"14","author":"Lin","year":"2008","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.beha.2013.09.003_bib20","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/rheumatology\/ker137","article-title":"A\u00a0case of Behcet's disease associated with myelodysplastic syndrome involving trisomy 8 and a gain of function mutation in SHP 2","volume":"50","author":"Shigemura","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.beha.2013.09.003_bib21","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/rheumatology\/ken162","article-title":"Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8","volume":"47","author":"Ahn","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.beha.2013.09.003_bib22","first-page":"814","article-title":"Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders","volume":"9","author":"Ladizinski","year":"2010","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.beha.2013.09.003_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3324\/haematol.2011.044347","article-title":"Value of infliximab (Remicade(R)) in patients with low risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group","volume":"97","author":"Baron","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2013.09.003_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0049-0172(92)90035-C","article-title":"Seronegative inflammatory arthritis in the myelodysplastic syndromes","volume":"21","author":"George","year":"1992","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.beha.2013.09.003_bib25","first-page":"11","article-title":"Manifestations rhumatologiques associ\u00e9es aux syndromes my\u00e9lodysplasiques et my\u00e9loprolif\u00e9ratifs","volume":"59","author":"Pajus","year":"1992","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"10.1016\/j.beha.2013.09.003_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s100670200081","article-title":"Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship?","volume":"21","author":"Espinosa","year":"2002","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.beha.2013.09.003_bib27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/rheumatology\/35.5.496","article-title":"Polymyalgia rheumatica as the rheumatological manifestation of myelodysplastic syndrome in a Chinese patient","volume":"35","author":"Mok","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.beha.2013.09.003_bib28","first-page":"685","article-title":"Temporal arteritis masquerading as chronic myelomonocytic leukemia","volume":"21","author":"Rizos","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.beha.2013.09.003_bib29","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/archderm.142.9.1170","article-title":"Chronic recurrent lymphocytic sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases","volume":"142","author":"Vignon Pennamen","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.beha.2013.09.003_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMcpc1104568","article-title":"Case records of the Massachusetts General Hospital. Case 1 2012. An 82 year old man with persistent ulcers on the hands","volume":"366","author":"Kroshinsky","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2013.09.003_bib31","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/0002-9343(87)90229-4","article-title":"Sweet's syndrome and malignancy","volume":"82","author":"Cohen","year":"1987","journal-title":"Am J Med"},{"issue":"2 Suppl. 1","key":"10.1016\/j.beha.2013.09.003_bib32","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/j.jaad.2004.12.041","article-title":"Thalidomide in the treatment of recalcitrant Sweet's syndrome associated with myelodysplasia","volume":"53","author":"Browning","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.beha.2013.09.003_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2141.1993.tb03083.x","article-title":"Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease","volume":"84","author":"Reuss Borst","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2013.09.003_bib34","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3324\/haematol.2010.030536","article-title":"Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes","volume":"96","author":"Feng","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2013.09.003_bib35","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0301-472X(02)00921-9","article-title":"CD40L induces proliferation, self renewal, rescue from apoptosis, and production of cytokines by CD40 expressing AML blasts","volume":"30","author":"Aldinucci","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.beha.2013.09.003_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2141.1993.tb08668.x","article-title":"Sweet's syndrome associated with G CSF","volume":"85","author":"Paydas","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2013.09.003_bib37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/ard.2006.068254","article-title":"Efficacy of anakinra, an IL1 receptor antagonist, in refractory sweet syndrome","volume":"67","author":"Delluc","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.beha.2013.09.003_bib38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s10156-003-0254-6","article-title":"Successful treatment of pyoderma gangrenosum that developed in a patient with myelodysplastic syndrome","volume":"9","author":"Yamauchi","year":"2003","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.beha.2013.09.003_bib39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2133.1994.tb08467.x","article-title":"Simultaneous occurrence of two rare cutaneous markers of poor prognosis in myelodysplastic syndrome: erythema elevatum diutinum and specific lesions","volume":"131","author":"Aractingi","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.beha.2013.09.003_bib40","first-page":"731","article-title":"Association of myelodysplastic syndrome and relapsing polychondritis: further evidence","volume":"9","author":"Hebbar","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2013.09.003_bib41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7326\/0003-4819-104-1-74","article-title":"Relapsing polychondritis. Survival and predictive role of early disease manifestations","volume":"104","author":"Michet","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2013.09.003_bib42","first-page":"1208","article-title":"Myelodysplasia and relapsing polychondritis","volume":"22","author":"Piette","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.beha.2013.09.003_bib43","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.3899\/jrheum.110665","article-title":"Relapsing polychondritis associated refractory airway stenosis","volume":"38","author":"Lai","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.beha.2013.09.003_bib44","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<200::AID-AJH6>3.0.CO;2-0","article-title":"Myelodysplastic syndromes with nephrotic syndrome","volume":"60","author":"Saitoh","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2013.09.003_bib45","doi-asserted-by":"crossref","first-page":"661","DOI":"10.7326\/0003-4819-117-8-661","article-title":"The association between the myelodysplastic syndromes and Crohn disease","volume":"117","author":"Eng","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2013.09.003_bib46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000262292","article-title":"Pulmonary alveolar proteinosis as a terminal complication in a case of myelodysplastic syndrome with idic (20q )","volume":"123","author":"Xue","year":"2010","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2013.09.003_bib47","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000083454","article-title":"Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion","volume":"113","author":"Giagounidis","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2013.09.003_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000072413","article-title":"Cyclosporine A in the treatment of a patient with immune thrombocytopenia accompanied by myelodysplastic syndrome and nephrotic syndrome","volume":"110","author":"Park","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2013.09.003_bib49","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/sj.leu.2402129","article-title":"Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases","volume":"15","author":"Bourgeois","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2013.09.003_bib50","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2007-01-067546","article-title":"CD4+CD25+high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)","volume":"110","author":"Kordasti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib51","first-page":"5","article-title":"Immune mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones","volume":"45","author":"Maciejewski","year":"2007","journal-title":"Folia Histochem Cytobiol"},{"key":"10.1016\/j.beha.2013.09.003_bib52","first-page":"150","article-title":"Immunological abnormalities in myelodysplastic syndromes","volume":"33","author":"Hamblin","year":"1996","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beha.2013.09.003_bib53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1756-185X.2012.01704.x","article-title":"Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis","volume":"15","author":"Kim","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.beha.2013.09.003_bib54","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood.V99.5.1594","article-title":"In\u00a0vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for fas dependent apoptosis","volume":"99","author":"Claessens","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2005-05-1884","article-title":"Interferon gamma induced gene expression in CD34 cells: identification of pathologic cytokine specific signature profiles","volume":"107","author":"Zeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib56","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2005-05-1989","article-title":"NF kappaB constitutes a potential therapeutic target in high risk myelodysplastic syndrome","volume":"107","author":"Braun","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib57","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood.V85.11.3183.bloodjournal85113183","article-title":"Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine mediated hematopoietic suppression in\u00a0vitro","volume":"85","author":"Maciejewski","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib58","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1158\/1078-0432.CCR-06-0254","article-title":"Effect of cA2 anti tumor necrosis factor alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes","volume":"12","author":"Boula","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2013.09.003_bib59","first-page":"429","article-title":"Cytokine targets in the treatment of myelodysplastic syndromes","volume":"4","author":"Verma","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.beha.2013.09.003_bib60","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.leukres.2011.03.027","article-title":"Effects of thalidomide on long term bone marrow cultures from patients with myelodysplastic syndromes: induction of IL 10 expression in the stromal layers","volume":"35","author":"Lazarini","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2013.09.003_bib61","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood.V98.10.3058","article-title":"Expression of tumor necrosis factor related apoptosis inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in\u00a0vitro hemopoiesis","volume":"98","author":"Zang","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib62","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2008-02-139824","article-title":"Inhibition of the TGF beta receptor I kinase promotes hematopoiesis in MDS","volume":"112","author":"Zhou","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib63","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2005-04-1424","article-title":"NF kappaB and FLIP in arsenic trioxide (ATO) induced apoptosis in myelodysplastic syndromes (MDSs)","volume":"106","author":"Kerbauy","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib64","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0301-472X(02)00968-2","article-title":"Autologous lymphocytes inhibit haemopoiesis in long term culture in patients with myelodysplastic syndrome","volume":"30","author":"Baumann","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.beha.2013.09.003_bib65","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/blood-2005-04-1543","article-title":"Evidence for reduced B cell progenitors in early (low risk) myelodysplastic syndrome","volume":"106","author":"Sternberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib66","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.leukres.2008.03.019","article-title":"A\u00a0case of myelodysplastic syndrome associated with CD14(+)CD56(+) monocytosis, expansion of NK lymphocytes and defect of HLA E expression","volume":"33","author":"Ruggiero","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2013.09.003_bib67","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3324\/haematol.2012.074823","article-title":"The effects of 5 azacytidine on the function and number of regulatory T cells and T effectors in myelodysplastic syndrome","volume":"98","author":"Costantini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2013.09.003_bib68","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/leu.2008.333","article-title":"Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS)","volume":"23","author":"Kotsianidis","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2013.09.003_bib69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","article-title":"IL 17 producing CD4(+) T cells, pro inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome","volume":"145","author":"Kordasti","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2013.09.003_bib70","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3324\/haematol.11812","article-title":"Activation of cytotoxic T cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes","volume":"93","author":"Kiladjian","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2013.09.003_bib71","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.leu.2404080","article-title":"Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes","volume":"20","author":"Kiladjian","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2013.09.003_bib72","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1182\/blood-2006-07-035519","article-title":"Reduced natural killer (NK) function associated with high risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors","volume":"109","author":"Epling Burnette","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib73","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/leu.2009.279","article-title":"Testing the NKT cell hypothesis in lenalidomide treated myelodysplastic syndrome patients","volume":"24","author":"Chan","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2013.09.003_bib74","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/1042819021000055345","article-title":"Immunosuppressive treatments for myelodysplastic syndromes","volume":"44","author":"Shimamoto","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2013.09.003_bib75","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2141.1997.4423249.x","article-title":"Antithymocyte globulin for patients with myelodysplastic syndrome","volume":"99","author":"Molldrem","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2013.09.003_bib76","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","article-title":"Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care SAKK 33\/99","volume":"29","author":"Passweg","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.09.003_bib77","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190410001723322","article-title":"Remicade as TNF suppressor in patients with myelodysplastic syndromes","volume":"45","author":"Raza","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2013.09.003_bib78","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Myelodysplastic Syndrome 003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2013.09.003_bib79","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion dependent, low risk, and intermediate 1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib80","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2008-08-175778","article-title":"Efficacy and safety of lenalidomide in intermediate 2 or high risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study","volume":"113","author":"Ad\u00e8s","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.09.003_bib81","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.leukres.2004.11.008","article-title":"Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes","volume":"29","author":"Invernizzi","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2013.09.003_bib82","first-page":"3415","article-title":"Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: results of a phase II trial","volume":"32","author":"Chung","year":"2012","journal-title":"Anticancer Res"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T04:35:39Z","timestamp":1596602139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692613000510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1521692613000510"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2013.09.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): Cause or consequence?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2013.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}